Core Insights - U.S. stocks experienced an upward trend, with the Nasdaq Composite increasing by over 1% on Monday [1] - WW International, Inc. announced a partnership with Amazon Pharmacy to enhance access to weight management medications, resulting in a significant rise in its stock price [1] Company Performance - WW International shares surged by 12.5%, reaching $30.28 on Monday following the announcement of the partnership [2] - Replimune Group, Inc. saw its shares jump by 103.5% to $9.16 after the FDA accepted its Biologics License Application resubmission for RP1 [4] - Celcuity Inc. experienced a 46.1% increase in stock price to $75.93 after presenting positive Phase 1 data at ESMO 2025 [4] - American Battery Technology Company shares rose by 26.3% to $6.13 [4] - Canaan Inc. gained 25% to $2.0007 [4] - Datavault AI Inc. increased by 21% to $2.1650 following a partnership announcement [4] - GRAIL, Inc. jumped 21% to $94.29 after announcing a $325 million private placement financing [4] - Other notable gains included Bit Digital, Inc. at 21% to $4.4500, Kodiak Sciences Inc. at 17.4% to $16.56, and Recursion Pharmaceuticals, Inc. at 17% to $6.84 [4]

Core Viewpoint - A class action securities lawsuit has been filed against 3D Systems Corporation, alleging securities fraud that negatively impacted investors between August 13, 2024, and May 12, 2025 [1][2]. Group 1: Allegations of Fraud - The lawsuit claims that 3D Systems Corporation understated the impact of weakened customer spending on its business while overstating its resilience in challenging industry conditions [2]. - It is alleged that updated milestone criteria in the partnership with United Therapeutics Corporation would adversely affect the revenue from the Company's regenerative medicine program [2]. - As a result, the Company's public statements were deemed materially false and misleading throughout the relevant period [2]. Group 2: Legal Process and Participation - Investors who suffered losses during the specified timeframe have until August 12, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [3]. - Class members may be entitled to compensation without incurring any out-of-pocket costs or fees, and there is no obligation to participate [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4].

Financial Data and Key Metrics Changes - For Q4 2024, consolidated revenues were $111 million, a decline of 3% year-over-year, primarily due to a $9 million decrease from a change in accounting estimate [53][54] - Full-year revenues for 2024 totaled $440 million, down 10% from the previous year, impacted by broader macro pressures on printer sales [56] - Non-GAAP gross margin for Q4 was 31.3%, down from 39.8% in the prior year, with a full-year gross margin of 37.4%, compared to 40.6% in 2023 [58][59] Business Line Data and Key Metrics Changes - Industrial Solutions revenues grew 11% in Q4 to $71 million, driven by strength in printer systems sales and services, particularly in aerospace and defense [54] - Healthcare Solutions reported Q4 revenues of $40 million, down 21% year-over-year, influenced by the accounting change and inventory management issues among dental customers [55][57] - Full-year revenues for Industrial Solutions were $250 million, a decline of 9%, while Healthcare Solutions revenues were $190 million, down approximately 11% [56][57] Market Data and Key Metrics Changes - The aerospace and defense markets showed significant growth, contributing to the uptick in industrial printer sales [54][72] - The dental market is expected to see substantial growth, particularly in the aligner segment, with a projected addressable market of over $1 billion in the U.S. alone by 2029 [33][35] Company Strategy and Development Direction - The company is focusing on in-sourcing manufacturing operations to gain control over product introduction, costs, and quality, which is expected to yield long-term competitive advantages [22][23] - A strategic emphasis is placed on high-reliability markets such as automotive, aerospace, and medical devices, with plans to expand on these markets in future earnings releases [18][19] - The company aims to improve profitability through cost reduction initiatives targeting over $50 million in annualized savings by mid-2026 [42][44] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the challenging macroeconomic environment affecting customer CapEx spending, but noted signs of stabilization and strengthening demand in Q4 [15][16] - The company expects revenues for 2025 to be flat to modestly growing, with significant improvements in profitability anticipated due to cost actions [50][67] - Management expressed confidence in long-term growth prospects driven by advancements in additive technology and increased customer interest in production applications [20][21] Other Important Information - The company announced a divestiture of its Geomagic Software platform for $123 million, expected to close shortly, which will enhance its balance sheet [45][64] - Cash and cash equivalents at year-end 2024 were $171 million, down from $332 million in the prior year, with significant cash used for debt repurchases [64][65] Q&A Session Summary Question: Update on the industrial vertical and Q1 expectations - Management noted an encouraging uptick in new printer sales in Q4, particularly in high-reliability markets, but expects Q1 to be seasonally weaker [72][75] Question: Focus on dental business and revenue expectations - Management indicated that while aligners will dominate in 2025, significant revenue from other segments like dentures is expected to ramp up in 2026 [80][82] Question: Cost cuts and their impact on growth opportunities - Management confirmed that most cost cuts are permanent and focused on efficiency improvements, with minimal expected revenue impact [114][116] Question: Cash flow expectations and timeline for positive cash flow - Management aims for operating cash flow positivity in 2026, with improvements expected as cost savings are realized [120][121]